Fat and bone are never alone: osteoporotic fracture in RA Dr. David Liew discusses Abstract 889 at #ACR22. Abstract 88

Tweet Author

Tweet Content

Fat and bone are never alone: osteoporotic fracture in RA Dr. David Liew discusses Abstract 889 at #ACR22. Abstract 889: Serum Adipokines Predict Incident Osteoporotic Fracture in Patients with Rheumatoid Arthritis https://t.co/4IrdQBq1z2 https://t.co/2HySVG1SGY

Links

https://bit.ly/3UhZVGU

Topic Podcasts #ACR22 - SpA Part3 -Opioids and Health Care Utilization in PsA and AS -Reproductive health in a post-Ro

Tweet Author

RheumNow

Tweet Content

Topic Podcasts #ACR22 - SpA Part3 -Opioids and Health Care Utilization in PsA and AS -Reproductive health in a post-Roe world -SpA: Novel Therapies, Diagnostic Dilemmas and Depression -Tapering TNFi in nonradiographic AxSpA and more https://t.co/hXPlQaxPWs https://t.co/2SRYS6EOr7

Links

https://bit.ly/3VjQc4g

29 November 2022

Low Dose IL-2 Therapy in Sjögren’s

There is a large, unmet need in treating Sjögren’s syndrome, yet a new randomized clinical trial has shown that low-dose interleukin 2 (LD-IL-2) was effective effective and well tolerated in patients with primary Sjögren’s syndrome (pSS), with evidence of restored immune balance.

How Underweight Women Can Reduce Hip Fracture Risk https://t.co/Czf3YJbD2r https://t.co/xKaZPTTOcS

Tweet Author

RheumNow

Tweet Content

How Underweight Women Can Reduce Hip Fracture Risk https://t.co/Czf3YJbD2r https://t.co/xKaZPTTOcS

Links

https://bit.ly/3VFRO8t

Tyk2 Inhibition Effective in SLE Deucravacitinib, an oral, selective TYK2 inhibitor, has demonstrated efficacy in a ph

Tweet Author

RheumNow

Tweet Content

Tyk2 Inhibition Effective in SLE Deucravacitinib, an oral, selective TYK2 inhibitor, has demonstrated efficacy in a phase II trial active systemic lupus erythematosus (SLE) patients. https://t.co/cpbDnkfUIS https://t.co/xct8dACBAY

Links

https://bit.ly/3XKtP9K

RCT data on BTK inhibitor evobrutinib shows it to be well tolerated. Ph 2 RCT data on 1083 pts (RA, MS, SLE) Rx w/ evob

Tweet Author

RheumNow

Tweet Content

RCT data on BTK inhibitor evobrutinib shows it to be well tolerated. Ph 2 RCT data on 1083 pts (RA, MS, SLE) Rx w/ evobrutinib(861) or placebo(271) for ~ 6 mos. No diff in TEAEs or EAIR , 2 deaths (SLE), SIE 2-3/100PY https://t.co/4HOTKuCAUi https://t.co/u7KSD6RN4q

Links

https://bit.ly/3ubpXB8

Study of 294 SLE pts on HCQ (2005-2021): 37 (13%) developed CHF w/ low EF (HFrEF), arrhythmia or cardiac death. After a

Tweet Author

RheumNow

Tweet Content

Study of 294 SLE pts on HCQ (2005-2021): 37 (13%) developed CHF w/ low EF (HFrEF), arrhythmia or cardiac death. After adjustments, wt-based dosing of HCQ not assoc w/ cardiac events(sHR 0.62; 0.41,0.92) & may decrease risk in non-smokers https://t.co/ufYcnuMI2r https://t.co/cOPIUpwpHf

Links

https://bit.ly/3AS3qNv

JAMA - Update/Review of Hemochromatosis Dx and Rx. - 5 gene defects in hepcidin. 95% HFE & the C282Y variant - 90%ar

Tweet Author

RheumNow

Tweet Content

JAMA - Update/Review of Hemochromatosis Dx and Rx. - 5 gene defects in hepcidin. 95% HFE & the C282Y variant - 90%are asymptomatic - Suspicion w/ arthralgias, LFTs, hepatomegaly, cardiomyopathy, 1st degr relative - Untreated, 9% risk of cirrhosis https://t.co/nuq8Ioralk https://t.co/djwlVsIk3b

Links

https://bit.ly/3EDapuS

#ACR22 - SpA Part2 -Comorbidities in Ankylosing Spondylitis -Early Diagnosis of AxSpA -Fertility issues in SpA -Gen

Tweet Author

RheumNow

Tweet Content

#ACR22 - SpA Part2 -Comorbidities in Ankylosing Spondylitis -Early Diagnosis of AxSpA -Fertility issues in SpA -Gender in AxSpa -Inadequate Dosing of HCQ Leads to Hospitalizations in SLE -JAK inhibitors in RD -Opioid use in PsA and SpA https://t.co/1xJzSmekR2 https://t.co/kxpLGi8Ky4

Links

https://bit.ly/3Vv0Ftq

29 November 2022

ACR22 Takeaways: Pre-RA, Lupus, PsA and AS

ACR22 Convergence left us bountiful with information from all over the world. Here are a few of my personal highlights and key takeaways.

Topics

Fat and bone are never alone: osteoporotic fracture in RA Dr. David Liew discusses Abstract 889 at #ACR22. Abstract 88

Topic Podcasts #ACR22 - SpA Part3 -Opioids and Health Care Utilization in PsA and AS -Reproductive health in a post-Ro

How Underweight Women Can Reduce Hip Fracture Risk https://t.co/Czf3YJbD2r https://t.co/xKaZPTTOcS

Tyk2 Inhibition Effective in SLE Deucravacitinib, an oral, selective TYK2 inhibitor, has demonstrated efficacy in a ph

RCT data on BTK inhibitor evobrutinib shows it to be well tolerated. Ph 2 RCT data on 1083 pts (RA, MS, SLE) Rx w/ evob

Study of 294 SLE pts on HCQ (2005-2021): 37 (13%) developed CHF w/ low EF (HFrEF), arrhythmia or cardiac death. After a

JAMA - Update/Review of Hemochromatosis Dx and Rx. - 5 gene defects in hepcidin. 95% HFE & the C282Y variant - 90%ar

#ACR22 - SpA Part2 -Comorbidities in Ankylosing Spondylitis -Early Diagnosis of AxSpA -Fertility issues in SpA -Gen

Do you get our email newsletter?

Fat and bone are never alone: osteoporotic fracture in RA Dr. David Liew discusses Abstract 889 at #ACR22. Abstract 88

Topic Podcasts #ACR22 - SpA Part3 -Opioids and Health Care Utilization in PsA and AS -Reproductive health in a post-Ro

How Underweight Women Can Reduce Hip Fracture Risk https://t.co/Czf3YJbD2r https://t.co/xKaZPTTOcS

Tyk2 Inhibition Effective in SLE Deucravacitinib, an oral, selective TYK2 inhibitor, has demonstrated efficacy in a ph

RCT data on BTK inhibitor evobrutinib shows it to be well tolerated. Ph 2 RCT data on 1083 pts (RA, MS, SLE) Rx w/ evob

Study of 294 SLE pts on HCQ (2005-2021): 37 (13%) developed CHF w/ low EF (HFrEF), arrhythmia or cardiac death. After a

JAMA - Update/Review of Hemochromatosis Dx and Rx. - 5 gene defects in hepcidin. 95% HFE &amp; the C282Y variant - 90%ar

#ACR22 - SpA Part2 -Comorbidities in Ankylosing Spondylitis -Early Diagnosis of AxSpA -Fertility issues in SpA -Gen

JAMA - Update/Review of Hemochromatosis Dx and Rx. - 5 gene defects in hepcidin. 95% HFE & the C282Y variant - 90%ar